Clinical Decision Support Tool and Rapid Point-of-Care Platform for Determining Disease Severity in Patients with COVID-19

Michael P McRae; Glennon W Simmons; Nicolaos J Christodoulides; Zhibing Lu; Stella K Kang; David Fenyo; Timothy Alcorn; Isaac P Dapkins; Iman Sharif; Deniz Vurmaz; Sayli S Modak; Kritika Srinivasan; Shruti Warhadpande; Ravi Shrivastav; John T McDevitt

Therefore, there is a need for a series of diagnostic tests that collectively cover/monitor the entire timeline of infection. Here, three tests are relevant. The first is a molecular diagnostic that tests for the virus itself or part of the same. These tests include RT-PCR or immunological tests that are specific for a component of the virus such as the coronavirus spike glycoprotein. 29 Both assay modalities lend information on the amount of virus present during the initial stages of infection (i.e., days 2 to 20) but lack accurate quantitation information as the samples are often collected from a nasal swab where the sample volume is ill-defined. After this initial infection phase, the . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.